

TNX- 355

Drug Class: Entry and Fusion Inhibitors

TNX-355 is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells.

HIV/AIDS-Related Uses

TNX-355 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

TNX-355 comes in a liquid form that is given by intravenous infusion into a vein. Many different dosages based on body weight are being studied in clinical trials.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, TNX-355 may cause some unwanted effects. These side effects are not yet known. So far, TNX-355 has been well tolerated in limited human studies.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve TNX-355, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: TNX-355 AND HIV Infections.

Manufacturer Information

TNX-355
Tanox, Inc.
10555 Stella Link
Houston, TX 77025
(866) 312-5200

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET